The effect of Toxoplasma gondii infection in flunixin meglumine treated pregnant ewes as monitored by plasma levels of 15-ketodihydroprostaglandin F2 alpha, progesterone, oestrone sulphate and ultrasound scanning.
The aim of this study was to examine the endocrinological response (15-ketodihydro-PGF2 alpha, progesterone and oestrone sulphate) of pregnant ewes which were constantly treated with flunixin meglumine (FM) after infection with Toxoplasma gondii. Seven Swedish Peltsheep ewes were dosed orally with 2,000 T. gondii oocysts at 90.5 (82-94) days of pregnancy. The ewes were treated with FM, 1 mg/kg, intramuscularly twice a day, starting one day before infection until the end of the gestation period. Further three ewes were treated with FM alone during the corresponding time of pregnancy. Another four ewes were used as uninfected and untreated controls. All infected ewes developed antibodies to T. gondii and aborted, but the FM treated control group and the non-treated control group, which remained seronegative, delivered the lambs in the normal gestation range. No early abortions (less than 10 days after infection) were seen in the infected group. The endocrinological changes reflected the pathological changes in the uterus and foetuses. FM could neither completely inhibit prostaglandin release during abortion nor the physiological change of the hormone before parturition even though it depressed prostaglandin release before abortion or parturition and eliminated fever. The infectious process caused by the organism was probably not affected. FM treatment alone had no observed negative effects on pregnant ewes and their foetuses.
Aiumlamai
S
S
Department of Obstetrics and Gynaecology, Swedish University of Agricultural Sciences, Uppsala.
Fredriksson
G
G
Uggla
A
A
Kindahl
H
H
Edqvist
L E
LE
D000818:Animals; D003002:Clonixin / Q000031:analogs & derivatives / Q000627:therapeutic use*; D015237:Dinoprost / Q000031:analogs & derivatives / Q000097:blood; D004970:Estrone / Q000031:analogs & derivatives / Q000097:blood; D005260:Female; D009539:Nicotinic Acids / Q000627:therapeutic use*; D011247:Pregnancy; D011374:Progesterone / Q000097:blood; D012756:Sheep; D012757:Sheep Diseases / Q000188:drug therapy*; D014124:Toxoplasmosis, Animal / Q000188:drug therapy*; D014463:Ultrasonography / Q000662:veterinary
D009539:Nicotinic Acids; C008228:15-keto-13,14-dihydroprostaglandin F2alpha; D004970:Estrone; D011374:Progesterone; C014558:flunixin meglumine; D015237:Dinoprost; C017296:estrone sulfate; D003002:Clonixin